People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the average weight loss seen with semaglutide.

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...

Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.

Competition is brewing for Novo Nordisk and Eli Lilly, two of the world's leading pharmaceutical weight loss companies, according to analysts ... The potential business rivals are Roche, Amgen, Pfizer ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

For the second trading session in less than a week, Roche Holding ( RHHBY 3.83%) stock really took it on the chin Wednesday.

The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...